New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 28, 2014
11:08 EDTKERX, BBY, WB, MACK, RMTI, SHLD, DB, ARUN, WUBA, AZNOptions with decreasing implied volatility
Options with decreasing implied volatility: KERX WUBA ARUN DB SHLD RMTI MACK WB BBY AZN
News For KERX;WUBA;ARUN;DB;SHLD;RMTI;MACK;WB;BBY;AZN From The Last 14 Days
Check below for free stories on KERX;WUBA;ARUN;DB;SHLD;RMTI;MACK;WB;BBY;AZN the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
July 30, 2014
09:53 EDTBBYBest Buy CEO Joly says sales of tablets 'crashing,' Re/code reports
Subscribe for More Information
06:10 EDTAZNAstraZeneca enters respiratory disease transaction with Almirall
AstraZeneca announced that it has entered an agreement to transfer to the company the rights to Almirall’s respiratory franchise for an initial consideration of $875M on completion, and up to $1.22B in development, launch, and sales-related milestones. AstraZeneca has also agreed to make various sales-related payments. Upon completion of the transaction, AstraZeneca will own the rights for the development and commercialization of Almirall’s existing proprietary respiratory business, including rights to revenues from Almirall’s existing partnerships, as well as its pipeline of investigational novel therapies. The franchise includes Eklira, LAS40464, LAS100977 or abediterol, and multiple pre-clinical programs. Under the agreement, Almirall Sofotec, an Almirall subsidiary focused on the development of innovative proprietary devices, will also transfer to AstraZeneca. Almirall’s pipeline of respiratory assets and its device capabilities further strengthen AstraZeneca’s respiratory portfolio, which includes Symbicort and Pulmicort, as well as the company’s investigational medicines in development. The addition of aclidinium and the combination of aclidinium with formoterol, both in proprietary Genuair device, will allow AstraZeneca to offer patients a choice between dry powder inhaler and metered dose inhaler devices across a range of molecules and combinations. AstraZeneca and Almirall anticipate that, subject to local consultation and legislation, a significant number of employees dedicated to the respiratory business, including Almirall Sofotec employees, will transfer to AstraZeneca. The transaction is subject to certain competition law clearances as well as other customary terms and conditions. The companies anticipate the transaction will complete by the end of 2014.Reference Link
July 29, 2014
18:35 EDTWBOn The Fly: After Hours Movers
Subscribe for More Information
14:18 EDTDBNY regulator seeks monitors in Deutsche Bank, Barclays, WSJ says
Subscribe for More Information
05:33 EDTDBDeutsche Bank reports Q2 net income EU 238M vs. EU 335M last year
Reports Q2 revenue EU 7.89B vs. EU 8.22B last year. Reports Common Equity Tier 1 ratio of 11.5% on a fully loaded Capital. Deutsche said its provision for credit losses declined 47% in Q2 to EU 250M compared to last year.
July 28, 2014
07:44 EDTDBInvestors looking for signs of Deutsche leveraging synergies, WSJ says
When Deutsche Bank reports its second quarter results Tuesday, investors will be looking for progress on the bank's stated goal of getting its investment bank and wealth-management business to work more to each other's benefit, said The Wall Street Journal. Reference Link
05:36 EDTAZNQIAGEN, AstraZeneca announce collaboration
QIAGEN (QGEN) announced a collaboration agreement with AstraZeneca (AZN) for the co-development and commercialization of a liquid biopsy-based companion diagnostic to be paired with IRESSA, AstraZeneca's targeted therapy for non-small cell lung cancer, or NSCLC. The project builds on a master framework agreement signed by both companies in 2013 and aims to develop and market a novel QIAGEN companion diagnostic that analyzes plasma samples to assess EGFR mutation status in NSCLC patients. The assay will be designed to guide the treatment of NSCLC patients with Astra Zeneca's oral monotherapy anti-cancer treatment when tumor tissue is not available. QIAGEN already offers the therascreen EGFR RGQ PCR Kit as a tissue-based companion diagnostic for lung cancer patients, which was approved in the U.S. by the FDA in July 2013 and in China in May 2014. The companies will collaborate to create a new companion diagnostic for IRESSA based on liquid biopsy samples from NSCLC patients, rather than requiring invasive surgical collection of tissue samples. Data from several studies, including the IFUM Study presented at the "World Lung 2013" conference, provided evidence of the ability to assess the EGFR status of advanced lung cancer patients using blood / plasma samples. This breakthrough provides hope for patients for whom surgical biopsy is not an option by enabling them to have their EGFR mutation status assessed using a less invasive method.
July 25, 2014
17:05 EDTDBHSBC, Deutsche Bank sued over manipulation of silver prices, Reuters reports
Reference Link
06:40 EDTDBLoan write down standards changed for non-U.S. banks, NY Times says
A new accounting rule will enable banks outside of the U.S. to write down the value of loans earlier but could cause loans to become less attractive for those banks, according to The New York Times. The rule was issued by the International Accounting Standards Board, whose guidelines are followed in more than 100 countries but not in America, the newspaper stated. Publicly traded European banks include Banco Santander (SAN), Barclays (BCS), Credit Suisse (CS), Deutsche Bank (DB), HSBC (HSBC), ING Groep (ING), Lloyds Banking (LYG), Royal Bank of Scotland (RBS) and UBS (UBS).Reference Link
July 24, 2014
17:17 EDTKERXKeryx up 3% in after hours trading after Zerenex meets phase 3 primary end-point
Subscribe for More Information
10:54 EDTWBChina's Weibo, Jumei advance after Citi starts coverage with Buy ratings
Subscribe for More Information
09:33 EDTWBWeibo initiated with a Buy at Citigroup
Subscribe for More Information
08:25 EDTDBDeutsche ability to pass U.S. stress tests questioned after warning, FT says
Subscribe for More Information
08:20 EDTDBDeutsche Bank CFO faces internal criticism over reporting, WSJ says
U.S. authorities have expressed serious concerns about Deutsche Bank's financial data, it has recently come to light, but the bank's CFO Stefan Krause has also faced criticism from within the organization about the issues, say people familiar with the discussions, reported The Wall Street Journal. Reference Link
July 22, 2014
15:32 EDTDBNY Fed said Deutsche Bank U.S. unit reports 'inaccurate, unreliable,' WSJ says
Subscribe for More Information
09:47 EDTWBWeibo initiated with a Buy at Tigress Financial
Subscribe for More Information
07:31 EDTDBSenate Homeland Security & Government Affairs Committee to hold a hearing
Subscribe for More Information
05:25 EDTAZNAdams Express, MedImmune announce clinical trial partnership
Advaxis (ADXS) has entered into a clinical trial collaboration with MedImmune, the global biologics research and development arm of AstraZeneca (AZN). The Phase I/II immunotherapy study will evaluate the safety and efficacy of MedImmune's investigational anti-PD-L1 immune checkpoint inhibitor, MEDI4736, in combination with Advaxis' lead cancer immunotherapy vaccine, ADXS-HPV, as a treatment for patients with advanced, recurrent or refractory human papillomavirus, or HPV,-associated cervical cancer and HPV-associated head and neck cancer. Both MEDI4736 and ADXS-HPV are cancer immunotherapies, a new class of treatments that use the body's own immune system to help fight cancer. Under the terms of the agreement, MedImmune and Advaxis will evaluate the combination as a treatment for HPV-associated cervical cancer and squamous cell carcinoma of the head and neck. The Phase I part of the trial is expected to establish a recommended dose regimen of MEDI4736 with ADXS-HPV, and the Phase II portion will assess the safety and efficacy of the combination. The study will be funded and conducted by Advaxis. Results from the study will be used to determine whether further clinical development of this combination is warranted. Under the terms of the deal, MedImmune has a non-exclusive relationship with respect to HPV-driven tumour types. MedImmune has first right of negotiation for future development of combinations involving MEDI4736 and ADXS-HPV.
July 21, 2014
10:45 EDTBBYAnalysts roll out coverage on GoPro with differing views
Shares of GoPro (GPRO) are climbing after a number of analysts initiated coverage of the stock with different outlooks. GoPro develops mountable and wearable cameras. BULLISH TAKE: JPMorgan analyst Paul Coster initiated coverage of GoPro with an Overweight rating. GoPro is gaining share in the digital camcorder market, and it has begun to penetrate "active lifestyle" markets, which are a much larger opportunity for the company, Coster believes. The company could ship 10M of its products for use by active lifestyle participants annually, the analyst estimated. In a best case scenario, the company could also sell low-cost devices for the mass market, according to Coster. However, GoPro will face competition from major companies, including Google (GOOG) and possibly Apple (AAPL) in this market, warned Coster, who set a $51 price target on GoPro. Also initiating coverage of the name with an Overweight rating was Piper Jaffray analyst Sean Naughton. GoPro is in the early stages of growth, as the company's user base is poised to expand beyond extreme sports enthusiasts, the analyst forecast. The company has a competitive advantage over other brands, which should enable it to maintain strong profitability, added Naughton, who set a $48 price target on the shares. BEARISH TAKE: Stifel analyst Jim Duffy started coverage of GoPro with a Hold rating. The company's three year growth outlook is compelling, but the stock is fully valued, the analyst believes. The company faces a number of risks, including competition in the image device market and the possibility that its relationship with key channel partners, including Best Buy (BBY), could be disrupted, the analyst wrote. Sales to Best Buy accounted for 17% of GoPro's revenue in fiscal 2013, Duffy reported. After GoPro surged following its initial public offering, the stock is likely to advance by only limited amounts, wrote Barcalys analyst Joseph Wolf, who initiated coverage of the shares with an Equal Weight rating. The stock could fall to $30 if the company is unable to increase its hardware sales or make progress in its efforts to develop a media business, the analyst warned. He set a $45 price target on the shares. PRICE ACTION: A total of seven analysts rolled out coverage today on GoPro, according to The Fly’s research, with only two recommending the stock with buy-equivalent ratings. Shares of the camera marker are up 3%, or $1.10, to $42.53 in morning trading.
July 18, 2014
06:26 EDTDBMetro hires Deutsche to guide on consumer-electronics unit, Bloomberg says
Metro (MTTRY) hired Deutsche Bank (DB) to examine options for its consumer-electronics unit, according to Bloomberg, citing two people with direct knowledge of the matter. The sources said that alternatives may include a sale, spinoff or IPO of the Media-Saturn division. Reference Link
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use